The CD44 receptor is a molecular predictor of survival in ovarian cancer (original) (raw)

Abstract

Purpose: CD44 is a cell surface receptor implicated in cancer progression and metastases. Malignant tumors may show a loss of CD44 splice control mechanisms. We investigated the role of CD44 splice variant expression in ovarian tumors and metastases, and its association with survival.

Experimental Design: We tested CD44 expression in 142 cases of epithelial carcinoma of the ovary and 265 metastatic sites by immunohistochemistry.

Results: Survival analysis showed that the expression of CD44s, CD44-v4,-v5, -v6, -v9, and -v10 are significant predictors for survival in univariate analysis. After stage, the expression of CD44-v10 in metastases was the strongest predictor of decreased survival in multivariate analysis (_p_=0.0009). Conversely, CD44-v10 expression in the primary tumor was an independent predictor of improved survival in multivariate analysis (_p_=0.0002). The expression of CD44s in the tumor/stroma interface of the primary tumor was associated with improved survival (p<0.0001).

Conclusions: CD44 variant expression is a molecular prognostic maker for epithelial ovarian carcinomas. CD44-v10 expression is an independent prognostic indicator and the site of expression determines a positive or negative influence in survival. Our results also indicate that CD44 may be involved in important tumor/stroma interactions.

Access this article

Log in via an institution

Subscribe and save

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kohn EC, Liotta LA. Molecular insights into cancer invasion: Strategies for prevention and intervention. Cancer Res 1995; 55:1856–1862.
    PubMed CAS Google Scholar
  2. Lee TH, Wisniewski HG, Vilcek J. A novel secretory tumor necrosis factor-inducible protein (TSG-6) is a member of the family of hyaluronate binding proteins, closely related to the adhesion receptor CD44. J Cell Biol 1992; 116:545–557.
    Article PubMed CAS Google Scholar
  3. Levesque MC, Haynes BF, TNFα and IL-4 regulation of hyaluronan binding to monocyte CD44 involves posttranslational modification of CD44. Cellular Immunology 1999; 193:209–218.
    Article PubMed CAS Google Scholar
  4. Gardner MJ, Jones L, Catterall J, Turner G. Expression of cell adhesion molecules on ovarian tumor cell lines and mesothelial cells in relation to ovarian cancer metastasis. Cancer Lett 1995; 91:229–234.
    Article PubMed CAS Google Scholar
  5. Chiu RK, et al. Alternatively spliced CD44 isoforms containing exon v10 promote cellular adhesion through the recognition of chondroitin sulfate-modified CD44. Experim Cell Res 1999; 248:213–321.
    Google Scholar
  6. Goodison S, Tarin D. Current status of CD44 variant isoforms as cancer diagnostic markers. Histopathology 1998; 32:1–6.
    Article PubMed CAS Google Scholar
  7. Rodríguez-Rodríguez L, et al. CD44 splice variant expression in clear cell carcinoma of the ovary. Gynecol Oncol 1998; 71:223–229.
    Article PubMed Google Scholar
  8. Darai E, et al. Analysis of CD44 expression in serous and mucinous borderline tumours of the ovary: Comparison with cystadenomas and overt carcinomas. Histopathology 1998; 32:151–159.
    Article PubMed CAS Google Scholar
  9. Ross JS, et al. Decreased CD44 standard form expression correlates with prognostic variables in ovarian carcinomas. Am J Clin Pathol 2001; 116:122–128.
    Article PubMed CAS Google Scholar
  10. Sancho-Torres I, Mesonero C, Miller-Watelet JL, Gibbon DG, Rodríguez-Rodríguez L. Clear cell carcinoma of the ovary. Characterization of its CD44 isoform repertoire. Gynecol Oncol 2000; 79:187–195.
    Article PubMed CAS Google Scholar
  11. Gibbon DG, et al. CD44 splice variants expression correlates with in vitro mestastatic potential in ovarian cancer cell lines. J Soc Gynecol Invest 1998; 5:82A-83A.
    Article Google Scholar
  12. Saegusa M, Machida D, Hashimura M, Okayasu I. CD44 expression in benign, pemalignant, and malignant ovarian neoplasms: Relation to tumour development and progression. J Pathol 1999; 189:326–337.
    Article PubMed CAS Google Scholar
  13. Mackay CR, et al. Expression and modulation of CD44 variant isoforms in humans. J Cell Biol 1994; 124:71–82.
    Article PubMed CAS Google Scholar
  14. Rösel M, Khaldoyanidi S, Zawadzki V, Zoller M. Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation. Exp Hematol 1999; 27:698–711.
    Article PubMed Google Scholar
  15. Iida N, Bourguignon LY. Coexpression of CD44 variant (v10/ex14) and CD44s in human mammary epithelial cells promotes tumorigenesis. J Cell Physiol 1997; 171:152–160.
    Article PubMed CAS Google Scholar
  16. Cannistra SA, De Franzo B, Niloff J., Ottensmeier C. Functional heterogeneity of CD44 molecules in ovarian cancer cells. Clin Cancer Res 1995; 1:333–342.
    PubMed CAS Google Scholar

Download references

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, The Cancer Institute of New Jersey, Division of Gynecologic Oncology, UMDNJ/Robert Wood Johnson Medical School, 08901, New Brunswick, NJ
    L. Rodríguez-Rodríguez M.D., Ph.D. (Chief of Gynecologic Oncology) & D. G. Gibbon
  2. Department of Obstetrics and Gynecology, Staten Island University Hospital, 10305, Staten Island, NY
    I. Sancho-Torres
  3. University of Rochester Medical Center, Rochester, NY
    C. Mesonero & G. Zotalis
  4. The Cancer Institute of New Jersey, Division of Biometrics, UMDNJ/ Robert Wood Johnson Medical School, 08901, New Brunswick, NJ
    W. J. Shih

Authors

  1. L. Rodríguez-Rodríguez M.D., Ph.D.
  2. I. Sancho-Torres
  3. C. Mesonero
  4. D. G. Gibbon
  5. W. J. Shih
  6. G. Zotalis

Rights and permissions

About this article

Cite this article

Rodríguez-Rodríguez, L., Sancho-Torres, I., Mesonero, C. et al. The CD44 receptor is a molecular predictor of survival in ovarian cancer.Med Oncol 20, 255–263 (2003). https://doi.org/10.1385/MO:20:3:255

Download citation

Key Words